Release Date: 15/11/19 19:08 Summary: Syntonic Revised Strategic Business Focus Price Sensitive: Yes Download Document 386.44KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%